Suiny;SK-0403;Anagliptin;Alagliptin;SUINY;SK-0403;Anagliptin API;Anagliptin (SK-0403);Anagliptin, 10 mM in DMSO;(S)-N-(2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethylaMino)-2-Methylpropyl)-2-Methylpyrazolo[1,5-a]pyriMidine-6-carboxaMide;(R)-N-(2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethylamino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.
Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved
in Japan in November 2012 for the treatment of patients with Type 2 diabetes
mellitus (T2DM).
Anagliptin (also known asSK-0403) is a treatment for diabetes based on inhibition of DPP-4, an enzyme that is responsible for degradation of glucagon-like peptide 1 (GLP-1), a 30-amino acid peptide that is secreted in response to food intake. GLP-1 stimulates
insulin secretion and inhibits glucagon secretion, which leads to lower
levels of plasma glucose. Following the introduction of the first DPP-4 inhibitor, sitagliptin, in 2006, several members of the gliptin class have been approved worldwide. Anagliptin was discovered from an effort to replace
a metabolically labile isoindoline group from an earlier DPP-4 inhibitor series with a stable bioisostere. Anagliptin is a potent DPP-4 inhibitor, with an IC50=3.8 nM and >10,000-fold selectivity over inhibition of DPP-8 and DPP-9.
Clinical Use
Anagliptin, which is marketed as Beskoa or Suiny, is a dipeptidyl peptidase–IV (DPP-4) inhibitor
which was approved in September 2012 and launched in November 2012 in Japan for the treatment of
Type II diabetes. The drug was co-developed by three Japanese companies; Kowa, Sanwa Kagaku and
JW pharmaceutical. Anagliptin, which is more selective against several recombinant human proteases by comparison to sitagliptin and vildagliptin, has more than 10,000-fold selectivity over the
structurally homologous DPP-8 and DPP-9 enzymes.
Anagliptin Upstream-Materialien And Downstream Produkte
Anagliptin-d7Q: What is
Anagliptin-d7 Q: What is the CAS Number of
Anagliptin-d7 Q: What is the storage condition of
Anagliptin-d7 Q: What are the applications of
Anagliptin-d7
AnagliptinQ: What is
Anagliptin Q: What is the CAS Number of
Anagliptin Q: What is the storage condition of
Anagliptin Q: What are the applications of
Anagliptin
Alagliptin
Anagliptin, 10 mM in DMSO
739366-20-2
Copyright 2019 ? ChemicalBook. All rights reserved
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment(File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)